# First In Human Study of CX-2051 in Advanced Solid Tumors

> **NCT06265688** · PHASE1 · RECRUITING · sponsor: **CytomX Therapeutics** · enrollment: 160 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** CX-2051
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06265688
- **Lead sponsor:** CytomX Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2027-11-30
- **Final completion:** 2029-03-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265688, "First In Human Study of CX-2051 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06265688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*